Tag: Seeking
-
GSK’s First Biologic Treatment For Asthma – Nucala Holds Multi-Billion Dollar Potential – Seeking Alpha
GSK's First Biologic Treatment For Asthma – Nucala Holds Multi-Billion Dollar PotentialSeeking AlphaNucala was recently approved by the USFDA and EMA for the treatment of patients with severe Asthma of eosinophilic phenotype. In the base case, Nucala should reach peak sales of $2b. If Nucala is approved in other indications (COPD, HES) too, it can ……
-
Teva’s asthma candidates successful in three late-stage studies; regulatory … – Seeking Alpha
Teva's asthma candidates successful in three late-stage studies; regulatory …Seeking AlphaTop-line results from three Phase 3 clinical trials assessing Teva Pharmaceutical Industries' (TEVA +0.4%) fluticasone propionate/salmeterol, a combination inhaled corticosteroid and long-acting beta agonist delivered via a multidose dry powder inhaler … View full post on asthma – Google News
-
FDA clears Teva asthma med (TEVA) – Seeking Alpha (registration)
Nasdaq FDA clears Teva asthma med (TEVA)Seeking Alpha (registration)The FDA approves Teva Pharmaceutical Industries' (NYSE:TEVA) ProAir RespiClick (albuterol sulfate) inhalation powder for the treatment or prevention of bronchospasm in patients at least 12 years old with reversible obstructive airway disease and for …Teva Announces FDA Approval of ProAir® RespiClickBusiness Wire (press release)Teva Announces FDA Approval…
-
Investors appear to wake up to potential of BioTime’s Asthma iPhone app (BTX) – Seeking Alpha (registration)
Investors appear to wake up to potential of BioTime's Asthma iPhone app (BTX)Seeking Alpha (registration)Thinly-traded small cap BioTime (BTX +16.1%) jumps on a 4x surge in volume in (what appears to be) belated response to the March 9 announcement by Mount Sinai's Icahn School of Medicine that it is launching a large-scale research study of…
-
A Quick Review Of The Asthma Market – Seeking Alpha (registration)
A Quick Review Of The Asthma MarketSeeking Alpha (registration)Asthma remains a major health concern, with the WHO estimating the number of people suffering from asthma at 235 million. In the U.S., the CDC reports asthma prevalence at 9% in children and 8% in adults (CDC 2012). Even social media trends identify a … View full post…
-
Sanofi/Regeneron asthma drug successful in Phase 2 trial – Seeking Alpha (registration)
Sanofi/Regeneron asthma drug successful in Phase 2 trialSeeking Alpha (registration)The three highest doses of dupilumab in combination with standard-of-care therapy met the primary endpoint of a statistically significant improvement from baseline in forced expiratory volume over one second (FEV1) at week 12 in patients with high … View full post on asthma – Google News
-
Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In … – Seeking Alpha
Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In …Seeking AlphaAfter the close of the markets on Wednesday, October 9, 2013, Dynavax (DVAX) announced it will begin dosing patients in the first human trial in its asthma program. The trial, which is being conducted under a collaborative agreement with AstraZeneca … View full post…
-
Regeneron’s New Asthma Drug And Its Fierce Competitors – Seeking Alpha
Regeneron's New Asthma Drug And Its Fierce CompetitorsSeeking AlphaThere are a large variety of asthma drugs on the market, but the most they can do is alleviate symptoms. They do little about the substance of the disease. Dupilumab, an injectable medication being developed by Regeneron Pharmaceuticals (REGN) and … View full post on asthma – Google…
-
Clearing The Air On The Sanofi-Regeneron Asthma Drug Trial – Seeking Alpha
Clearing The Air On The Sanofi-Regeneron Asthma Drug TrialSeeking AlphaResults announced this week of a clinical trial testing the drug dupilumab, made by the biotechnology company Regeneron Pharmaceuticals (REGN) and global pharmaceutical company Sanofi (SNY) gave hope to asthma sufferers and got the attention of … View full post on asthma – Google News
-
Dynavax Advances Agonist For Asthma Into The Clinic – Seeking Alpha
Dynavax Advances Agonist For Asthma Into The ClinicSeeking AlphaDynavax Technologies Corporation (DVAX) announced this morning it will advance its proprietary second-generation TLR-9 agonist for asthma into Phase 1 clinical studies. The work will be performed under the terms of a collaboration with AstraZeneca …Dynavax to Initiate Phase 1 Studies for TLR-9 Agonist for AsthmaEquities.comall 7…